Keyphrases
Chronic Lymphocytic Leukemia
100%
COVID-19
27%
Hospitalized Patients
20%
Remdesivir
17%
Low Risk
14%
Ibrutinib
13%
Overall Survival
13%
Clinical Outcomes
13%
Tumor Protein p53 (TP53)
13%
Infection Risk
13%
Gene mutation
12%
National Cohort Study
12%
Eosin-5-maleimide
11%
Improved Survival
11%
Bounds Test
11%
Richter Transformation
11%
Fluorescent Beads
11%
Time-to-treatment
11%
Multiple Myeloma
11%
Confidence Interval
10%
Prognostic Factors
9%
Innate Immune Response
9%
Pre-diagnostic
9%
Diffuse Large B-cell Lymphoma (DLBCL)
9%
30-day Mortality
8%
Venetoclax
8%
Immunoglobulin
8%
Progression-free Survival
7%
Targeted Therapy
7%
Newly Diagnosed Patients
7%
High Risk
7%
Clinical Impact
7%
Risk Factors
7%
TP53 mutation
6%
Clinical Data
6%
Standard of Care
6%
Prognostic Impact
6%
Phase II Trial
6%
Next-generation Sequencing
6%
Time to First Treatment
6%
Higher Order Connections
5%
Effect Modifier
5%
Clinical Infectious Diseases
5%
Test Performance
5%
Deep Targeted Sequencing
5%
Patients with COVID-19
5%
Multi-hit
5%
Hazard Ratio
5%
Deletional
5%
Palestinian Family
5%
Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
70%
Infection
23%
COVID-19
23%
Remdesivir
11%
Richter's Transformation
11%
Cohort Analysis
11%
Dexamethasone
11%
Clinical Trial
8%
Ibrutinib
8%
Venetoclax
8%
Prognostic Factor
7%
Targeted Therapy
7%
Diagnosis
6%
Disease
6%
Somatic Hypermutation
5%
Lymphocytosis
5%
Immune Function
5%
4 Iodo 2,5 Dimethoxyamphetamine
5%
Immunoglobulin
5%
Next Generation Sequencing
5%
Eosin
5%
Gene Mutation
5%
Treatment Effect
5%
Minimal Residual Disease
5%
Hazard Ratio
5%
Maleimide
5%
Time to Treatment
5%
Omicron Coronavirus Variant
5%
Multiple Myeloma
5%
Non-Hodgkin Lymphoma
5%
